Important concerns in the management of severe asthma identified at the European Respiratory Biologics Forum

How can biomarkers and phenotypes be best identified and utilised in daily clinical practice?
Is the ACQ the right tool for monitoring the response to biologics?
Is treatment response assessed using the ACQ related to the effect of treatment on exacerbations?
How can awareness be raised among patients and non-specialists regarding the burden of oral corticosteroids and the potential of new treatments available?
Are oral steroids effective in patients having exacerbations while on biological therapies?
When should patients start and stop taking a biologic?
When should patients be switched from one biologic to another?

ACQ: Asthma Control Questionnaire.